Vesynta Limited

Vesynta Limited, based in Sutton, UK, is a small, active company founded six years ago in 2019. Employing eight people and holding £99,023 in assets, it operates from a real address and is overseen by two directors and owners. The company is an irregular importer, primarily dealing with optical and medical tools and devices, with just one month of imports recorded as of January 2022.

The company's website highlights its focus on "DataGuided Precision Dosing" for healthcare. It’s not an e-commerce site, but rather a platform offering “DosoLogic,” a digital dosing assistant. This technology aims to improve patient outcomes by providing personalized drug recommendations based on data analysis. The website details how DosoLogic integrates with electronic health records, offers actionable dosing insights, and maximizes therapeutic potential while minimizing adverse events. The company targets oncology, anti-infectives, and immunology therapy areas. The site also features leadership profiles and a contact form.

Financially, Vesynta Limited presents a mixed picture. While cash reserves increased significantly by 110% to £45,000, net assets decreased by 320% to -£210,000. Creditors surged by 240% to £310,000, and trade debtors increased dramatically by 670%. The number of employees has also decreased by 25% to six. The company’s small size (meeting two of three criteria for turnover under £10.2m, assets under £5.1m, and fewer than 50 employees) allows for agility, but the substantial equity decline suggests a need for careful management. As a small company, it’s exempt from an audit, so the figures are unaudited. It’s clear that the company is burning through cash, and the large increase in creditors indicates a reliance on external financing.

Registered in England/Wales under the registration number 11859034, with a registered address at SM2 5NG, England, Sutton, Surrey, Innovation Gateway (The London Cancer Hub), Cotswold Road.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.